HansBiomed Corporation

KOSDAQ:A042520 Stock Report

Market Cap: ₩119.5b

HansBiomed Past Earnings Performance

Past criteria checks 0/6

HansBiomed's earnings have been declining at an average annual rate of -17.9%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been growing at an average rate of 2.9% per year.

Key information

-17.9%

Earnings growth rate

-15.4%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate2.9%
Return on equity-11.6%
Net Margin-8.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

HansBiomed Corporation's (KOSDAQ:042520) Low P/S No Reason For Excitement

Dec 09
HansBiomed Corporation's (KOSDAQ:042520) Low P/S No Reason For Excitement

Is HansBiomed (KOSDAQ:042520) A Risky Investment?

Oct 29
Is HansBiomed (KOSDAQ:042520) A Risky Investment?

Is HansBiomed (KOSDAQ:042520) A Risky Investment?

Feb 29
Is HansBiomed (KOSDAQ:042520) A Risky Investment?

HansBiomed Corporation (KOSDAQ:042520) Shares Fly 25% But Investors Aren't Buying For Growth

Feb 29
HansBiomed Corporation (KOSDAQ:042520) Shares Fly 25% But Investors Aren't Buying For Growth

Are Dividend Investors Making A Mistake With HansBiomed Corporation (KOSDAQ:042520)?

Apr 10
Are Dividend Investors Making A Mistake With HansBiomed Corporation (KOSDAQ:042520)?

Does HansBiomed (KOSDAQ:042520) Have A Healthy Balance Sheet?

Mar 06
Does HansBiomed (KOSDAQ:042520) Have A Healthy Balance Sheet?

HansBiomed's(KOSDAQ:042520) Share Price Is Down 63% Over The Past Three Years.

Jan 30
HansBiomed's(KOSDAQ:042520) Share Price Is Down 63% Over The Past Three Years.

Are HansBiomed's (KOSDAQ:042520) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Dec 08
Are HansBiomed's (KOSDAQ:042520) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Declining Stock and Decent Financials: Is The Market Wrong About HansBiomed Corporation (KOSDAQ:042520)?

Nov 20
Declining Stock and Decent Financials: Is The Market Wrong About HansBiomed Corporation (KOSDAQ:042520)?

Revenue & Expenses Breakdown

How HansBiomed makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A042520 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2481,137-7,22343,2944,628
30 Jun 2480,639-9,49343,9934,464
31 Mar 2478,291-10,00243,1624,858
31 Dec 2378,321-19,69441,5595,178
30 Sep 2378,032-23,04540,6235,597
30 Jun 2378,561-9,85237,7366,151
31 Mar 2380,309-9,96838,5006,111
31 Dec 2276,9913,15237,4656,098
30 Sep 2274,4596,14736,0675,658
30 Jun 2268,200-10,34837,2105,860
31 Mar 2263,498-11,63935,7036,482
31 Dec 2158,284-22,37336,4316,934
30 Sep 2159,098-18,28938,0777,148
30 Jun 2170,297-25,59344,3666,797
31 Mar 2173,649-23,62643,0186,040
31 Dec 2080,678-16,68640,9375,621
30 Sep 2080,098-17,84037,9955,511
30 Jun 2072,2935,25926,4975,462
31 Mar 2071,3957,53925,4535,098
31 Dec 1969,0439,86723,9204,703
30 Sep 1966,9919,95122,3324,038
30 Jun 1964,7685,52121,9833,170
31 Mar 1961,5015,25319,8312,526
31 Dec 1856,9454,50817,7931,497
30 Sep 1851,7464,15914,8121,147
30 Jun 1846,8666,75710,532920
31 Mar 1842,2975,6238,598850
31 Dec 1739,9776,1507,566645
30 Sep 1739,0587,8287,492777
30 Jun 1737,2696,6608,113330
31 Mar 1734,6116,7567,761284
31 Dec 1632,2966,3737,599398
30 Sep 1629,0484,6256,971177
30 Jun 1627,4944,9116,702361
31 Mar 1626,3375,3646,031323
31 Dec 1524,1184,8565,406326
30 Sep 1523,4284,9094,969369
30 Jun 1523,0054,2715,057536
31 Mar 1522,7263,8785,230533
31 Dec 1421,4513,6215,076524
30 Sep 1421,0333,4984,995513
30 Jun 1421,1244,1164,490191
31 Mar 1420,6233,7104,117178
31 Dec 1321,0994,2094,054182

Quality Earnings: A042520 is currently unprofitable.

Growing Profit Margin: A042520 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A042520 is unprofitable, and losses have increased over the past 5 years at a rate of 17.9% per year.

Accelerating Growth: Unable to compare A042520's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A042520 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).

Return on Equity

High ROE: A042520 has a negative Return on Equity (-11.62%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 04:23
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

HansBiomed Corporation is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jong Kyung ChoiDAOL Investment & Securities Co., Ltd.
Sang-Hun LeeiM Securities
Seung Kyu JungKiwoom Securities Co., Ltd.